Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation

Transplantation

Volumn 77, Issue 12, 2004, Pages 1777-1782

  Guba, Markus ^a   Graeb, Christian ^a   Jauch, Karl Walter ^a   Geissler, Edward K ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; FINGOLIMOD; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; TEMSIROLIMUS;

ALLOGRAFT; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER GROWTH; CLINICAL PROTOCOL; DOSE RESPONSE; DRUG EFFECT; GRAFT REJECTION; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALIGNANT NEOPLASTIC DISEASE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW;

ADRENAL CORTEX HORMONES; ANTINEOPLASTIC AGENTS; CALCINEURIN; CARCINOGENS; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SIROLIMUS; TRANSPLANTATION IMMUNOLOGY;

EID: 2442635905     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000120181.89206.54     Document Type: Review

References (74)

1. Sheil AGR. Cancer Report 1997. In: Disney APS, ed. The 20th annual report of the Australian and New Zealand Dialysis and Transplant Registry. Queen Elizabeth Hospital, Adelaide, South Australia 1997, p 138.
2. Ramsay HM, Fryer AA, Hawley CM, et al. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 2002; 147: 950.
3. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. In: Cecka JM, Terasaki PI, eds. Clinical Transplants 1998. Los Angeles, UCLA Tissue Typing Laboratory 1998: 147.
4. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681.
5. Hunt SA. Malignancy in organ transplantation: heart. Transplant Proc 2002; 34: 1874.
6. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40: 177.
7. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514.
8. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725.
9. Kehrl JH, Wakefield LM, Roberts AB, et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 2003; 163: 1037.
10. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994; 331: 365.
11. Masuhara M, Ogasawara H, Katyal SL, et al. Cyclosporine stimulates hepatocyte proliferation and accelerates development of hepatocellular carcinomas in rats. Carcinogenesis 1993; 14: 1579.
12. Shimizu T, Martin MS, Pelletier H, et al. Effects of cyclosporin A on progressive and regressive tumors induced by two cancer lines derived from a single colon carcinoma chemically induced in the rat. Immunobiology 1989; 178: 401.
13. Van de Vrie W, Marquet RL, Eggermont AM. Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumour. J Cancer Res Clin Oncol 1997; 123: 21.
14. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530.
15. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128.
16. Shihab FS, Bennett WM, Isaac J, et al. Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity. Kidney Int 2003; 63: 522.
17. Tanner JE, Menezes J. Interleukin-6 and Epstein-Barr virus induction by cyclosporine A: potential role in lymphoproliferative disease. Blood 1994; 84: 3956.
18. Walz G, Zanker B, Melton LB, et al. Possible association of the immunosuppressive and B cell lymphoma-promoting properties of cyclosporine. Transplantation 1990; 49: 191.
19. Herman M, Weinstein T, Korzets A, et al. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 2001; 137: 14.
20. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623.
21. Tremblay F, Fernandes M, Habbab F, et al. Malignancy after renal transplantation: incidence and role of type of immunosuppression. Ann Surg Oncol 2002; 9: 785.
22. Vivarelli M, Bellusci R, Cucchetti A, et al. Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation 2002; 74: 1746.
23. Freise CE, Ferrell L, Liu T, et al. Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma. Transplantation 1999; 67: 510.
24. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001; 358: 1042.
25. Twentyman PR, Fox NE, White DJ. Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. Br J Cancer 1987; 56: 55.
26. Lin HL, Lui WY, Liu TY, et al. Reversal of Taxol resistance in hepatoma by cyclosporin A: involvement of the PI-3 kinase-AKT 1 pathway. Br J Cancer 2003; 88: 973.
27. Schumacher G, Oidtmann M, Rosewicz S, et al. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant Proc 2002; 34: 1392.
28. Jonas S, Rayes N, Neumann U, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 2003; 80: 1141.
29. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003; 76: 597.
30. Eng CP, Sehgal SN, Vézina C. Activity of Rapamycin (AY-22,989) against transplanted tumors. J Antibiot 1984; 37: 1231.
31. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001; 98: 10314.
32. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001; 15: 807.
33. Aoki M, Blazek E, Vogt PK. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A 2001; 98: 136.
34. Luan FL, Hojo M, Maluccio M, et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002; 73: 1565.
35. Nourse J, Firpo E, Flanagan WM, et al. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994; 372: 570.
36. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003; 3: 371.
37. Majewski M, Korecka M, Kossev P, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A 2000; 97: 4285.
38. Majewski M, Korecka M, Joergensen J, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 75: 1710.
39. Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 2003; 63: 4472.
40. Chen H, Lee JM, Zong Y, et al. Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors. J Virol 2001; 75: 2929.
41. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878.
42. Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 2001; 86: 23.
43. Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003; 63: 917.
44. Kahan BD, Knight R, Schoenberg L, et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc 2003; 35: S25-S34.
45. Budde K, Schmouder RL, Brunkhorst R, et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002; 13: 1073.
46. Brinkmann V, Pinschewer DD, Feng L, et al. FTY720: altered lymphocyte traffic results in allograft protection. Transplantation 2001; 72: 764.
47. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346.
48. Suzuki S, Enosawa S, Kakefuda T, et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation 1996; 61: 200.
49. Wang JD, Takahara S, Nonomura N, et al. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate 2003; 40: 50.
50. Tanaka T, Takahara S, Hatori M, et al. A novel immunosuppressive drug, FTY720, prevents the cancer progression induced by cyclosporine. Cancer Lett 2002; 181: 165.
51. Azuma H, Takahara S, Ichimaru N, et al. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res 2002; 62: 1410.
52. Matsuoka Y, Nagahara Y, Ikekita M, et al. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br J Pharmacol 2003; 138: 1303.
53. Permpongkosol S, Wang J-D, Takahara S, et al. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. Int J Cancer 2002; 98: 167.
54. Walker SE, Anver MR, Schechter SL, et al. Prolonged lifespan and high incidence of neoplasms in NZB/NZW mice treated with hydrocortisone sodium succinate. Kidney Int 1978; 14: 151.
55. Trattner A, Hodak E, David M, et al. The appearance of Kaposi sarcoma during corticosteroid therapy. Cancer 1993; 72: 1779.
56. Cai J, Zheng T, Lotz M, et al. Glucocorticoids induce Kaposi's sarcoma cell proliferation through the regulation of transforming growth factor-β. Blood 1997; 89: 1491.
57. Jensen MK, Soborg M. Chromosome aberrations in human cells following treatment with Imuran. Preliminary report. Acta Med Scand 1966; 179: 249.
58. Casey TP. Azathioprine (Imuran) administration and the development of malignant lymphomas in NZB mice. Clin Exp Immunol 1968; 3: 305.
59. Penn I, Hammond W, Brettschneider L, et al. Malignant lymphomas in transplantation patients. Transplant Proc 1969; 1: 106.
60. Bottomley WW, Ford G, Cunliffe WJ, et al. Aggressive squamous cell carcinomas developing in patients receiving long-term azathioprine. Br J Haematol 1995; 133: 460.
61. Lewis P, Hazleman BL, Hanka R, et al. Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine. Ann Rheum Dis 1980; 39: 457.
62. Scharf J, Nahir M, Eidelman S, et al. Carcinoma of the bladder with azathioprine therapy. JAMA 1997; 237: 152.
63. Krutchik AN, Buzdar AU, Tashima CK. Azathioprine and breast carcinoma. JAMA 1978; 239: 107.
64. Schneck SA, Penn I. De-novo brain tumours in renal-transplant recipients. Lancet 1971; 1: 983.
65. McGeown MG, Douglas JF, Middleton D. One thousand renal transplants at Belfast City Hospital: post-graft neoplasia 1968-1999, comparing azathioprine only with cyclosporin-based regimes in a single centre. In: Cecka JM, Terasaki PI, eds. Clinical Transplants 2000. Los Angeles, UCLA Tissue Typing Laboratory 2000: 193.
66. Montagnino G, Lorca E, Tarantino A, et al. Cancer incidence in 854 kidney transplant recipients from a single institution: comparison with normal population and with patients under dialytic treatment. Clin Transpl 1996; 10: 461.
67. Haberal M, Karakayali H, Emiroglu R, et al. Malignant tumors after renal transplantation. Artif Organs 2002; 26: 778.
68. Williams RH, Lively DH, DeLong DC, et al. Mycophenolic acid: antiviral and antitumor properties. J Antibiot 1968; 21: 463.
69. Sweeney MJ, Hoffman DH, Esterman MA. Metabolism and biochemistry of mycophenolic acid. Cancer Res 1972; 32: 1803.
70. Tressler RJ, Garvin LJ, Slate DL. Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo. Int J Cancer 1994; 57: 568.
71. Yokoyama I, Hayashi S, Kobayashi T, et al. Immunosuppressive drugs and their effect on experimental tumor growth. Transpl Int 1995; 8: 251.
72. Hussein MM, Mooij JM, Roujouleh HM. Regression of post-transplant Kaposi sarcoma after discontinuing cyclosporin and giving mycophenolate mofetil instead. Nephrol Dial Transplant 2000; 15: 1103.
73. Vella JP, Sayegh MH. Maintenance pharmacological immunosuppressive strategies in renal transplantation. Postgrad Med J 1997; 73: 386.
74. Eberhard OK, Kliem V, Brunkhorst R. Five cases of Kaposi's sarcoma in kidney graft recipients: possible influence of the immunosuppressive therapy. Transplantation 1999; 67: 180.